Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485063 | 0.86 | AR (0.41) | ARALPLPLAAALPG | |
| SCHEMBL16532166 | 0.86 | AR (0.41) | ARALPLPLAAALPG | |
| SCHEMBL30961358 | 0.81 | KDM2B (0.44) | ARALPLPLAAALPG | |
| SCHEMBL22083730 | 0.78 | ALPL (0.38) | ALPLPLAAALPGPI4KAPI4K2B | |
| SCHEMBL19700911 | 0.78 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL317055 | 0.77 | — | — | |
| SCHEMBL12689153 | 0.77 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19700912 | 0.74 | CPB1 (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14008074 | 0.74 | MAP3K5 (0.31) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27654362 | 0.72 | CPB2 (0.38) | ALPLPLAAALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | AR 1573/4885ALPL 4470/4885PLAA 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.